The Cancer Drug Fund (CDF) is a dedicated source of funding in England for increasing patient access to high-cost cancer drugs, with a fixed budget of £340 million per year, operating since 2016.
The CDF follows the appraisal by the National Institute of Health and Care Excellence (NICE) which uses the methods and process for appraising Highly Specialised Technologies (HST) to provide a viable route to reimbursement for high-cost drugs.
Learn more on how England is managing CDF in this policy brief.
